TM38837

TM38837 is a new small molecule inverse inhibitor of the CB1 receptor Cannabinoid receptor. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.

TM38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists, for example rimonabant.